Giotrif gets EU approval – update
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim's targeted anticancer Giotrif (afatinib) has received EU approval for use in lung cancer. The company said it would launch Giotrif in EU countries as soon as possible, with the first due in the "coming few weeks".